Online Database of Chemicals from Around the World

双异丙吡胺
[CAS# 3737-09-5]

供应商
Sigma-Aldrich, Inc. 美国 询价快递  
+86 (21) 6141-5566 / 800-819-3336
ordercn@sial.com,
化学品生产商(1992 年起)
chemBlink 标准供应商(2018 年起)
卡博森斯化学科技 (苏州) 有限公司 中国 询价快递  
+86 (512) 6260-5585
sales@carbosynth.com
QQ 交流
化学品生产商(2006 年起)
化学品供销商(2006 年起)
chemBlink 标准供应商(2016 年起)
APIChem Technology Co., Ltd. 中国 询价快递  
+86 (571) 8678-2096
sales@apichemistry.com
化学品生产商(2009 年起)
Alfa Chemistry 美国 询价快递  
+1 (201) 478-8534
inquiry@alfa-chemistry.com
化学品供销商(2012 年起)
chemBlink 标准供应商(2012 年起)
Alsachim SAS 法国 询价快递  
+33 (368) 240-080
contact@alsachim.com
化学品生产商
BOC Sciences 美国 询价快递  
+1 (631) 485-4226
info@bocsci.com
Skype 聊天
化学品供销商
chemBlink 标准供应商(2010 年起)
ChemPacific Corp 美国 询价快递  
+1 (410) 633-5771
sales@chempacific.com
化学品生产商(1995 年起)
Fluorochem Ltd. 英国 询价快递  
+44 (1457) 860-111
enquiries@fluorochem.co.uk
化学品生产商
Glentham Life Sciences 英国 询价快递  
+44 (2033) 978-798
info@glenthamls.com
化学品供销商(2013 年起)
Ryan Scientific, Inc. 美国 询价快递  
+1 (843)-884-4911
sales@ryansci.com
化学品生产商
Santa Cruz Biotechnology, Inc. 美国 询价快递  
+1 (831) 457-3800
scbt@scbt.com
化学品生产商
ZereneX Molecular Ltd. 英国 询价快递  
+44 (1204) 527-700
sales@zerenex-molecular.com
化学品生产商
基本信息
产品分类 原料药 >> 循环系统用药 >> 抗心律失常药
产品名称 双异丙吡胺
英文名 Disopyramide Free Base
别名 4-(Diisopropylamino)-2-Phenyl-2-(2-Pyridyl)Butanamide; 4-(Diisopropylamino)-2-Phenyl-2-(2-Pyridyl)Butyramide; 4-(Di(Propan-2-Yl)Amino)-2-Phenyl-2-Pyridin-2-Yl-Butanamide
分子式 C21H29N3O
分子量 339.48
CAS 登录号 3737-09-5
EINECS 登录号 223-110-2
分子行输入简码 SMILES C1=CC=CC=C1C(C2=CC=CC=N2)(CCN(C(C)C)C(C)C)C(N)=O
国际化学标识码 InChI 1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
国际化学标识检索码 InChIKey UVTNFZQICZKOEM-UHFFFAOYSA-N
物理化学性质
密度 1.1±0.1g/cm3 (计算值)
沸点 505.2±50.0°C at 760 mmHg (计算值)
闪点 259.4±30.1°C (计算值)
安全数据
SDS 化学品安全技术说明书参考文本
参考文献
(1) Kenneth E. Thummel and Danny D. Shen. Percentage Binding in Plasma, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Bound in Plasma' (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Bound in Plasma' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (22), Heparin (Extensive), Lithium (0), Mycophenolate (MPA: 97.5), Prednisolone (90-95 (<200 ng/ml), ~70(>1 microgm/ml)) and Rapacuronium (50-88) have not been provided here. In all, 280 drugs and their 'Bound in Plasma' values (%) are given in the files here.
(2) Kenneth E. Thummel and Danny D. Shen. Peak Time, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Time' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in hours unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Peak-Time' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (1.3), Enoxaparin (3), Epoetin Alfa (SC: 18, IP:12), Etanercept (SC-SD:72(48-96)), Filgrastim (4-5.8), Heparin (3), Interferon Alfa (IM:3.8,SC:7.3), Interferon Beta (SC:1-8), Lithium (IR:0.5-3, SR:2-6), Mycophenolate (MPA: 1.1-2.2), Prednisolone (1.5+-0.5), Sargramostim (A,SC: 1-3, C,SC:1.5-4) and Streptokinase (0.9+-0.21) have not been provided here. In all, 270 drugs and their 'Peak-Time' values are given in the files here.
(3) Kenneth E. Thummel and Danny D. Shen. Urinary Excretion, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023Urinary Excretion (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Urinary Excretion values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (Low), Clavulanate (43+-14), Enoxaparin (43), Epoetin alfa (<3), Etanercept (Negligible), Heparin (Negligible), Lithium (95+-15), Mycophenolate (MPA: <1), Prednisolone (26+-9), Rapacuronium (6-22) and Streptokinase (0) have not been provided here. In all, 297 drugs and their Urinary Excretion values (%) are given in the files here.
(4) Kenneth E. Thummel and Danny D. Shen. Volume of Distribution, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Volume of Distribution' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in liters/kg units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Volume of Distribution' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (0.10+-0.01), Clavulanate (0.21+-0.05), Enoxaparin (0.12+-0.04), Epoetin Alfa (0.033+-0.013 (0.033-0.075)), Etanercept (0.11), Filgrastim (0.15), Heparin (0.058+-0.11) +- 0.1), Infliximab (0.043). Interferon Alfa (0.40+-0.19), Interferon Beta (2.9+-1.8), Lithium (0.66+-0.16), Mycophenolate (MPA: 3.6+-4), Prednisolone (0.42+-0.11), Rapacuronium (0.2-0.5), Sargramostim (A: -, C:2(0.4-18) liters/(m.m)) and Streptokinase (0.08+-0.04) have not been provided here. In all, 284 drugs and their 'Volume of Distribution' values are given in the files here.
(5) Kenneth E. Thummel and Danny D. Shen. Peak Concentration, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Concentrations' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. The units are indicated along with the values. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Structures (and values) for Alteplase (t-PA) (973+-133 ng/ml), Clavulanate (2.8 micro g/ml), Enoxaparin (ACLM: 145+-45 ng/ml, BCLM: 414+-87 ng/ml), Epoetin Alfa (SC: 176+-75 U/l, IP: 375+-123 U/l), Etanercept (IV:2.32 micro-g/ml, SC-SD:1.2 micro-g/ml, SC-MD 3 micro-g/ml), Filgrastim (SC: 4 and 49 ng/ml), Heparin (70+-39 ng/ml), Infliximab (118 micro-g/ml), Interferon Alfa (IV: ~13 ng/ml, IM: 2.0 (1.5-2.6) ng/ml, SC: 1.7 (1.2-2.3) ng/ml), Interferon Beta (IV: 1491+-659 IU/ml, SC: 40+-20 IU/ml), Lithium (IR: 1-2 mM, SR: 0.7-1.2 mM), Mycophenolate (MPA: 8-19 micro-g/ml), Prednisolone (458+-150 ng/ml), Rapacuronium (6-20 micro-g/ml), Sargramostim (A, IV: 5ng/ml, A, SC: 1.5 ng/ml, C, IV: 100 ng/ml, C, SC: 10 ng/ml) and Streptokinase (188+-58 IU/ml) have not been provided here. In all, 304 drugs and their 'Peak-Concentration' values are given in the files here.
市场分析报告
请浏览双异丙吡胺市场分析报告总目录
相关产品
4-(3H-双吖丙啶-3-基)...  3-(3-双吖丙啶基)苯酚  双氧威; (2-(4-苯氧基苯...  双氧铀(VI)硫酸盐  双氧铀(VI)原磷酸盐  双氧铀二乙酸盐二水合物  双氧铀甲酸盐  双氧铀氯化物  双氧铀硝酸盐  N,N'-双亚水杨基-1,2-...  N-[2-(双异丙基氨基)乙基...  2,4-双异丙基苯酚  双-一聚乙二醇-琥珀酰亚胺酯  双吲哚马来酰亚胺 I  双吲哚马来酰亚胺 II  双吲哚马来酰亚胺 IV; 2,...  双吲哚马来酰亚胺 IX 甲烷磺...  双吲哚马来酰亚胺 V; 1-甲...  双茚二酮  双硬脂酸铝; 二硬脂酸铝; 碱...